论文部分内容阅读
人类肝细胞癌是全球最常见和具有高致命性的癌症之一.中国的肝癌患者在全球居于首位,目前仍然没有找到有效的方法来治疗肝癌.近年,溶瘤痘病毒(vaccinia virus)由于其高效的抗癌效应,副反应较低和良好的安全性已成为一种癌症治疗的新方法,且已经广泛应用于癌症的治疗中.索拉非尼,一种新型的肿瘤激酶抑制剂,作为化疗药物可安全有效地治疗肝癌,且已应用于临床试验中.本实验将索拉非尼与溶瘤痘病毒联用并探究其在肝癌细胞中的抗肿瘤的效应.通过体外MTT,Hochest,流式细胞术,Western blot等细胞实验和体内小鼠移植瘤模型的建立以及免疫组化的分析,发现索拉非尼联合溶瘤痘病毒,可显著的抑制肿瘤细胞的生长,促进肿瘤细胞的凋亡.小鼠移植瘤模型结果表明,随着时间的延长,联合处理组的肿瘤大小有下降的趋势.联合使用索拉非尼和溶瘤痘病毒可能为一项肝癌治疗的新途径.
Human hepatocellular carcinoma is one of the most common and highly lethal cancers in the world.China has the highest number of liver cancer patients in the world and there is still no effective way to treat it.However, in recent years, vaccinia virus, Efficient anti-cancer effects, low side effects, and good safety have become a new approach to cancer treatment and have been widely used in the treatment of cancer.Sorafenib, a novel oncokinetic kinase inhibitor, Chemotherapy can safely and effectively treat liver cancer, and has been used in clinical trials.In this experiment, sorafenib combined with oncolytic poxvirus and explore its anti-tumor effect in liver cancer cells.Through in vitro MTT, Hochest, Flow cytometry, Western blot and other cell experiments and in vivo mouse xenograft model establishment and immunohistochemistry analysis found that sorafenib combined with oncolytic pox virus, can significantly inhibit the growth of tumor cells and promote tumor cell Apoptosis.The results of mouse xenograft model showed that with the extension of time, the tumor size of the combined treatment group showed a tendency to decrease.The combination of sorafenib and oncolytic poxvirus may be a hepatocellular carcinoma The new treatment approach.